Key result
Concomitant coronary artery disease was not a significant independent predictor of all-cause mortality in patients with hypertrophic cardiomyopathy (HR 0.864, p=0.400).
Why the study?
Data on patients with hypertrophic cardiomyopathy developing coronary artery disease are scarce, and the impact of CAD on HCM prognosis remains unknown.
Does the presence of coronary artery disease worsen all-cause mortality in patients with hypertrophic cardiomyopathy?
Cohort (n=2,268)
Yes
Does the presence of coronary artery disease worsen all-cause mortality in patients with hypertrophic cardiomyopathy?
Hazard Ratio: 0.864 (95% CI 0.615–1.214)
Absolute Event Rate: 16.26% vs 15.36%
p-value: p=0.400
The presence of concomitant coronary artery disease does not significantly impact long-term all-cause or cardiovascular mortality in patients with hypertrophic cardiomyopathy.
Background: There is a paucity of patients with hypertrophic cardiomyopathy (HCM) developed coronary artery disease (CAD), and the impact of CAD on the prognosis of HCM patients is unknown. Therefore, our real-world cohort study aimed to investigate prognosis of CAD in patients with HCM. Methods: A cohort study was undertaken in HCM patients from May 2003 to September 2021. A total of 2268 patients were enrolled, with a mean follow-up of 5.6 years (interquartile range 2.4-8.4 years). Outcome assessment was based on the all-cause mortality, cardiovascular mortality/cardiac transplantation and SCD. Results: Among the 2268 patients studied, 353(15.6%) died during a mean follow-up of 5.6 years. The patients were divided into CAD (n=504) and non-CAD (n=1764) groups. No difference in the all-cause mortality, cardiovascular mortality/cardiac transplantation or SCD between patients with CAD and no CAD (log-rank c 2 =0.201, P=0.654; log-rank c 2 =0.233, P=0.629; log-rank c 2 =1.523, P=0.217). In the Cox analysis, CAD was not a significant independent predictor of all-cause mortality, cardiovascular mortality/cardiac transplantation or SCD in patients with HCM. Conclusion: In conclusion, there was no significant differences in mortality between the HCM patients with and without CAD, indicating no effect of CAD on all-cause mortality, cardiovascular mortality/cardiac transplantation, and SCD in the present large-scale study.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2023) conducted a cohort in Hypertrophic cardiomyopathy (n=2,268). Coronary artery disease vs. No coronary artery disease was evaluated on All-cause mortality (HR 0.864, 95% CI 0.615-1.214, p=0.400). Concomitant coronary artery disease was not a significant independent predictor of all-cause mortality in patients with hypertrophic cardiomyopathy (HR 0.864, p=0.400).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: